Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.

24 Jun 2010

New poll illustrates difficult situations cancer patients face in affording needed health care

A new poll illustrates the difficulty that cancer patients, survivors and their families face in affording needed health care and paying for other basic necessities such as food and heat, underscoring the need to strongly implement the Affordable Care Act so that it works for people with cancer.

24 Jun 2010

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

Helix BioPharma Corp. today announced positive Phase II pharmacokinetic findings for Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

24 Jun 2010

OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.

23 Jun 2010

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.

22 Jun 2010

Inovio Pharmaceuticals set to be added to Russell 3000 Index

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the company is set to be added to the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, according to a preliminary list of additions updated on June 18 on www.russell.com.

21 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

The Republic of Equatorial Guinea (Republica de Guinea Ecuatorial, along with the United Nations Population Fund (UNFPA), is working to strengthen and equip health facilities throughout the country to boost access to reproductive health services. The rebuilding process includes the construction and renovation of health centers and maternity units as well as proper training for medical students.

19 Jun 2010

Hyperthermia in combination with particle therapy highlighted at DEGRO annual meeting

BSD Medical Corporation today announced that hyperthermia in conjunction with particle therapy was highlighted at the annual meeting of the German Society of Radiation Oncology, which was recently held in Magdeburg, Germany. A total of 2,500 scientists and radiation oncologists attended the meeting.

18 Jun 2010

Scientific American publishes article on "rebirth" of DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Scientific American magazine has published in its July issue an article entitled "DNA Drugs Come of Age." The article was co-authored by Dr. David Weiner, Chairman, Scientific Advisory Board, Inovio Pharmaceuticals, and Professor, Department of Pathology & Laboratory Medicine, at the University of Pennsylvania and Dr. Matthew Morrow, a post-doctorate research fellow at University of Pennsylvania.

17 Jun 2010

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

GAVI Alliance's plan to introduce new vaccine projects in the developing world "is under threat amid the international economic downturn," the Financial Times reports. "Subsidies to extend the use of vaccines against rubella, HPV to tackle cervical cancer, cholera and Japanese encephalitis in the developing world are among those likely to be cancelled or delayed," according to GAVI's CEO Julian Lob-Levyt, the newspaper writes.

17 Jun 2010

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.

15 Jun 2010

Study: Millions of cancer survivors put off care they can't afford

The Associated Press: A new study says about 2 million of the 12 million cancer survivors in the United States put off medical care because they cannot afford it. "The study is being called the first to estimate how often current and former patients have skipped getting care because of money worries. It was led by Kathryn Weaver, a researcher at Wake Forest University Baptist Medical Center in Winston-Salem, N.C.

15 Jun 2010

Researchers report 4 pillars of preventive medicine for AD

Although effective treatment for Alzheimer's disease has been slow to emerge, there has been substantial progress in identifying AD risk factors and developing treatments that might delay or prevent onset of the disease. In a Special Issue of the Journal of Alzheimer's Disease, "Basics of Alzheimer's Disease Prevention," researchers report on key findings that point towards possible significant interventions.

14 Jun 2010

Guided Therapeutics' stock now trading on OTCBB under the symbol GTHP

Guided Therapeutics, Inc. today announced that its stock is now trading on the OTCBB under the symbol GTHP, following approval of the listing by the Financial Industry Regulatory Authority.

11 Jun 2010

HL survivors do not receive recommended cancer screening tests: Study

A population-based study of 2,071 Hodgkin lymphoma survivors over 15 years has discovered that while many survivors had multiple X-rays and CT scans years after treatment was finished, they often did not receive recommended cancer screening tests.

11 Jun 2010

Budget cuts, poor fiscal management threaten breast cancer screening for needy women

The California State Auditor released an audit today of California's Every Woman Counts (EWC) program that suggests the state's ability to adequately provide breast cancer screening for its neediest women is threatened by budget cuts and poor fiscal management, according to the seven California Affiliates of Susan G. Komen for the Cure®, the global leader of the breast cancer movement.

11 Jun 2010

Research may lead to better treatments for depression and substance abuse

In what has been hailed as a breakthrough, scientists from Columbia University Medical Center and Weill Cornell Medical College have outlined the molecular mechanism of membrane transport. The research shows how a protein transforms its shape to transport substances across the cell membrane in order to regulate transmission of the brain's messages across the synaptic gap from one neuron to another.

11 Jun 2010

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced that it has received approval for its SPR-based HPV-DNA chip from the State Food and Drug Administration of China (the "SFDA").

10 Jun 2010

Experts call on international community to commit attention and resources to cervical cancer prevention

Women's health leaders today called on the international community to commit the resources needed to ensure that women and girls worldwide have equal access to cervical cancer prevention technologies. At the WOMEN DELIVER conference, the Declaration for Universal Access to Cervical Cancer Prevention was issued by leading women's health, cancer and business organizations, including PATH, the International Planned Parenthood Federation and the International Union Against Cancer.

9 Jun 2010

Cervical Cancer News and Research

Further Reading

Zetiq completes clinical trial of CellDetect technology for early identification of cervical cancer

New poll illustrates difficult situations cancer patients face in affording needed health care

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

SynCon DNA vaccine shows advantages in magnitude and breadth of immune responses in non-human primates

Inovio Pharmaceuticals set to be added to Russell 3000 Index

SAHM strongly recommends HPV vaccines for males

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

Hyperthermia in combination with particle therapy highlighted at DEGRO annual meeting

Scientific American publishes article on "rebirth" of DNA vaccines

Financial Times examines how GAVI's $2.6B shortfall might affect new vaccine programs in developing countries

Inovio commences immunization in U.S. Phase I clinical trial of SynCon H5N1 influenza DNA vaccine

Study: Millions of cancer survivors put off care they can't afford

Researchers report 4 pillars of preventive medicine for AD

Guided Therapeutics' stock now trading on OTCBB under the symbol GTHP

HL survivors do not receive recommended cancer screening tests: Study

Budget cuts, poor fiscal management threaten breast cancer screening for needy women

Research may lead to better treatments for depression and substance abuse

SFDA approves China Medical Technologies' SPR-based HPV-DNA chip

Experts call on international community to commit attention and resources to cervical cancer prevention

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News